Imeik Technology Development Co (300896) investor relations material

Executive summary

• Revenue for H1 2026 was ¥1,215.74 million, down 6.42% year-over-year; net profit attributable to shareholders was ¥593.37 million, down 24.84% year-over-year.

• Gross margin remained high, but sales and management expenses increased due to new product launches and organizational expansion.

• The company maintained a strong R&D focus, with R&D expenses at ¥140.14 million, 11.53% of revenue.

• Major product launches included the approval and market entry of a botulinum toxin product and a radiofrequency skin treatment device.

• Cash dividend of ¥10 per 10 shares was proposed, totaling ¥301.43 million, representing 50.8% of H1 net profit.

Financial highlights

• Operating income: ¥1,215.74 million, down 6.42% year-over-year.

• Net profit attributable to shareholders: ¥593.37 million, down 24.84% year-over-year.

• Operating cash flow: ¥534.90 million, down 18.32% year-over-year.

• Total assets: ¥9,179.02 million, up 3.04% from year-end 2025.

• Gross margin for core products remained above 86%, with gel and solution injectables above 92%.

Outlook and guidance

• The company expects new product launches to enrich its portfolio and drive future growth.

• Continued investment in R&D and international expansion is planned.

• Management anticipates ongoing industry competition and regulatory tightening, but aims to leverage product innovation and brand strength.